Short-term treatment with monoclonal anti-tumor necrosis factor-α antibody in refractory long-standing rheumatoid arthritis.

被引：0
|
作者：
Fantini, F
Sinigaglia, L
Zeni, S
Cagnoli, M
Favalli, EG
Colombelli, P
机构：
来源：
ARTHRITIS AND RHEUMATISM | 2000年 / 43卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
964
引用
收藏
页码：S227 / S227
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-α treatment
    Higashida, J
    Wun, T
    Schmidt, S
    Naguwa, SM
    Tuscano, JM
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (11) : 2109 - 2115
  • [22] Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis
    Ziolkowska, M
    Maslinski, W
    CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (03) : 267 - 273
  • [23] Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis
    Tak, PP
    Taylor, PC
    Breedveld, FC
    Smeets, TJM
    Daha, MR
    Kluin, PM
    Meinders, AE
    Maini, RN
    ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1077 - 1081
  • [24] Severe Refractory Rheumatoid Arthritis Successfully Treated with Combination Rituximab and Anti-Tumor Necrosis Factor-α-Blocking Agents
    Koumakis, Eugenie
    Wipff, Julien
    Avouac, Jerome
    Kahan, Andre
    Allanore, Yannick
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (09) : 2125 - 2126
  • [25] Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
    Antoni, C
    Kalden, JR
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : S73 - S77
  • [26] Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody
    Gonzalez-Juanatey, C
    Testa, A
    Garcia-Castelo, A
    Garcia-Porrua, C
    Llorca, J
    Gonzalez-Gay, MA
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (03): : 447 - 450
  • [27] Population pharmacokinetics of golumumab.: A human anti-tumor necrosis factor-α monoclonal antibody, in patients with psoriatic arthritis
    Xu, Z.
    Vu, T.
    Lee, H.
    Ling, J.
    Hu, C.
    Baker, D.
    Beutler, A.
    Pendley, C.
    Wagner, C. I.
    Davis, H. M.
    Zhou, H.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1112 - 1112
  • [28] Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-α antibody compared with methotrexate in long-standing rheumatoid arthritis
    Barrera, P
    van der Maas, A
    van Ede, AE
    Kiemeney, BALM
    Laan, RFJM
    van de Putte, LBA
    van Riel, PLCM
    RHEUMATOLOGY, 2002, 41 (04) : 430 - 439
  • [29] Anti-tumor necrosis factor-α blockade improves insulin resistance in patients with rheumatoid arthritis
    Gonzalez-Gay, MA
    De Matias, JM
    Gonzalez-Juanatey, C
    Garcia-Porrua, C
    Sanchez-Andrade, A
    Martin, J
    Llorca, J
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2006, 24 (01) : 83 - 86
  • [30] The neuroendocrine system and rheumatoid arthritis:: Insights from anti-tumor necrosis factor-α therapy
    Sternberg, Esther M.
    Silverman, Marni N.
    Cizza, Giovanni
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1443 - 1445
12345